PMI Announces Plans to Scale Back Russian Operations

Apr.08.2022
PMI announces steps to suspend investments and reduce manufacturing operations in Russia, as well as plans to exit the market.

Following the announcement made on March 9, 2022, Philip Morris International Inc. (NYSE: PM) announced today the specific measures they have taken to temporarily halt investment plans and reduce their manufacturing business in Russia. PMI has taken the following actions:


Philip Morris International (PMI) has stopped offering some cigarette products in the market and reduced manufacturing activities accordingly. It has also halted marketing activities in the country and cancelled plans to launch all products, including its IQOS ILUMA flagship heated tobacco product in Russia by 2022. Plans to produce over 20 billion TEREA sticks (used for IQOS ILUMA) in Russia and invest $150 million have also been cancelled. Additionally, PMI's board of directors and senior executives are exploring options for an orderly exit from the Russian market due to the increasingly complex and rapidly changing regulatory and operational environment.


In the past four weeks, our main focus and all efforts have been to ensure the safety and security of our colleagues in Ukraine. We stand in solidarity with innocent men, women, and children who are suffering. "We employ over 3,200 people in Russia," said CEO Jacek Olczak. "We will continue to support them, including paying their salaries, and we will fulfill our legal obligations. Our priority will be to make decisions based on their safety and security.


As previously reported, Russia accounted for nearly 10% of PMI's total shipments in 2021, representing approximately 6% of the company's net income. PMI is set to release its Q1 2022 earnings announcement on April 21, 2022, which will include updated financial projections for the year.


Philip Morris International: Achieving a Smoke-Free Future


Philip Morris International (PMI) is a leading international tobacco company committed to achieving a smoke-free future and long-term development of its investment portfolio to include products beyond the tobacco and nicotine sectors. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including non-combustible heated, vapor, and orally consumed nicotine products, sold in markets outside the United States. Since 2008, PMI has invested over $9 billion to develop, scientifically validate, and commercialize smoke-free products for adult smokers who would otherwise continue smoking, with the goal of completely phasing out cigarette sales. This includes establishing world-class scientific evaluation capabilities, particularly in pre-clinical systematic toxicology, clinical and behavioural research, and post-market studies. The United States Food and Drug Administration (FDA) has authorized PMI's IQOS platform 1 device and consumables for marketing as a modified risk tobacco product (MRTP), concluding that the exposure modifications are appropriate for promoting public health. As of December 31, 2021, PMI's smoke-free products are available in 71 markets, and PMI estimates that approximately 15.3 million adult smokers have switched to IQOS and quit smoking globally. With a strong foundation in life sciences and expertise, PMI announced in February 2021 its ambitious expansion into the healthcare and medical sector, offering innovative products and solutions to meet unmet patient and consumer needs.


Link to original article:


The Philip Morris International (PMI) has announced the specific steps it will take to reduce its business operations in the Russian Federation, as well as its intent to withdraw from the market.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Health Canada announced a recall of 24,950 China-made GTMBAR 45K disposable vaping devices on November 13, 2026, citing non-compliance with child-resistant packaging requirements. The devices were sold in Canada between December 2024 and October 2026 and feature a 20mL e-liquid system with a nicotine concentration of 20 mg/mL. No related incidents or injuries had been reported as of November 12. Quebec-based LK Vape is the Canadian importer and distributor, while Shenzhen GTM bar Electronic Technology Co., Ltd. holds the GTMBAR trademark registration in the United Kingdom.
Regulations
Nov.16
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Juul Labs displayed its JUUL2 e-cigarette system alongside existing products, age-verification messaging and mobile coupons, 2Firsts observed. The JUUL2 device and Virginia Tobacco and Polar Menthol pods received FDA marketing authorization in August 2026. Booth materials highlighted longer battery life, greater e-liquid capacity and connected-device features. A TruAge sign and a mobile coupon presentation also featured at the booth, with weekly offers available to age-verified adult nicotine consumers at participating retailers.
EXPO
Oct.09